DETAILED ACTION
Status of Application, Amendments and/or Claims
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
The claim filed on 7/27/26 has been entered; no amendments are indicated.
Claims 1-3, 6, 19, 22, 24-25, 28, 38-39, 42, 52-53, 56, 66-67, 70, 91-92 and 96-97 are pending.
Election/Restrictions
Applicants' election without traverse of Group I, claims 1-3, 6, 19, 22, 24-25, 28, 38-39, 42, 52-53, 56, 66-67 and 70, in the reply filed on 7/27/26 is acknowledged.
Claims 91-92 and 96-97 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim.
The election without traverse of COL14A1 as the species of marker in the reply is also acknowledged. The elected species reads on each claim in the elected group.
Claims 1-3, 6, 19, 22, 24-25, 28, 38-39, 42, 52-53, 56, 66-67 and 70 are under consideration.
Specification
The disclosure is objected to because of the following informalities:
---At page 2, line 4, “lubular” should be “lobular”.
---At page 3, line 19, “ER positive” should be “ER-positive”.
---At page 39, line 2, the disclosure contains an embedded hyperlink (browser-executable code). Applicant is required to delete the embedded hyperlink; references to websites should be limited to the top-level domain name without any prefix such as http:// or other browser-executable code. See MPEP § 608.01 (VII).
Appropriate correction is required.
Claim Objections
Claims 1-3, 6, 19, 22, 38 and 42 are objected to for the following informalities:
In claim 1, line 8, the abbreviations “LA” and “LB1” should be accompanied by the full terminology the first time they appear in a series of claims; e.g., “luminal A (LA)-like” and “luminal B1 (LB1)-like”. Compare with claim 24, lines 1-2.
In claim 1, line 9, “ER positive” should be “ER-positive”. Compare with line 8.
In independent claim 38, line 1, the abbreviation “LA” and “LB1” should be accompanied by the full terminology the first time it appears in a series of claims; e.g., “luminal A (LA)”. Compare with claim 24, lines 1-2.
The remaining claim(s) are objected to for depending from an objected claim.
Appropriate correction is required.
Claim Rejections - 35 USC § 112(b)
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
Claims 1-3, 6, 19, 22, 24-25, 28, 38-39, 42, 52-53, 56, 66-67 and 70 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor, or for pre-AIA the applicant regards as the invention.
Claims 1, 6, 24, 28, 38, 42, 52, 56, 66 and 70 each expressly refer to Table 1 and/or Table 2 of the specification. Per MPEP § 2173.05(s), "[w]here possible, claims are to be complete in themselves. Incorporation by reference to a specific figure or table ‘is permitted only in exceptional circumstances where there is no practical way to define the invention in words and where it is more concise to incorporate by reference than duplicating a drawing or table into the claims. Incorporation by reference is a necessity doctrine, not for applicant's convenience.' Ex parte Fressola, 27 USPQ2d 1608, 1609 (Bd. Pat. App. & Inter. 1993)." In the instant case, the names of the proteins listed in the tables of the specification can be written out in the claims, and thus there is a practical way to define the invention in words. As such, each claim that references a table in the specification is herewith rejected under 35 U.S.C. 112(b).
The remaining claim(s) included in the rejection are dependent claims that depend from one of the claims rejected above and encompass the same indefinite subject matter.
Claim Rejections - 35 USC § 112, enablement
The following is a quotation of the first paragraph of 35 U.S.C. 112(a):
(a) IN GENERAL.-The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention.
The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112:
The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention.
Claims 1-3, 6, 19, 22, 24-25, 28, 38-39, 42, 52-53, 56, 66-67 and 70 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.
The factors considered when determining if the disclosure satisfies the enablement requirement and whether any necessary experimentation is “undue” include, but are not limited to: 1) nature of the invention, 2) state of the prior art, 3) relative skill of those in the art, 4) level of predictability in the art, 5) existence of working examples, 6) breadth of claims, 7) amount of direction or guidance by the inventor, and 8) quantity of experimentation needed to make or use the invention. In re Wands, 858 F.2d 731, 737, 8 USPQ2d 1400, 1404 (Fed. Cir. 1988).
The nature of the invention of independent claim 1, and claims depending therefrom, is a method with the intended goal of “determining a molecular subtype of an estrogen receptor (ER)-positive breast cancer in a subject”. Practicing the method of these claims involves two steps, as recited in independent claim 1, which are (a) detecting the level of the breast cancer marker in a biological sample from the subject, wherein the breast cancer marker comprises one or more markers selected from Table 1 and 2; and (b) comparing the level of the breast cancer marker in the biological sample with a predetermined threshold value, wherein the molecular subtype is luminal A (LA)-like or luminal B1 (LB1)-like and wherein the subtype is determined based on the level of the breast cancer marker above or below the predetermined threshold level. Independent claims 24 and 38, and claims depending therefrom, are directed to a method with the same method steps as claim 1, but with the goal of diagnosing the LA-like molecular subtype of LB1 breast cancer (claim 24) or the LB1-like molecular subtype of LA breast cancer (claim 38). Independent claims 52 and 66, and claims depending therefrom are directed to monitoring LA-like (claim 52) or LB-like (claim 66) breast cancer comprising three steps of detecting a breast cancer marker from Table 1 or 2 in two samples obtained at a first and second time points, and comparing the expression level between the two, with the change indicating progression of the breast cancer in the subject. The elected species of marker under consideration is the collagen XIV A1, a protein encoded by the gene COL14A1.
The specification discusses the prior art, teaching that breast cancer is “categorized into 3 major subtypes based on the presence or absence of molecular markers for estrogen or progesterone receptors (ER and PR, respectively) and human epidermal growth factor 2 (ERBB2, formerly HER2)” and that “there are different subtypes of ER-positive breast cancer, and each molecular subtype was shown to have distinct clinical outcomes” (¶ 6). The instant specification does not further clearly spell out the differences in these three types, but they are well known in the prior art as luminal A (ER/PR positive, HER2 negative, Ki-67 low); luminal B1 (ER positive, HER2 negative and either PR negative or Ki-67 high) and luminal B2 (ER positive, HER2 positive)(see the summary in Table 1 of Mota et al, 2024. Biomedicines. 12: 1371; pages 1-14 as printed). The teachings of the instant specification are limited to luminal A and B1; with ¶ 7 describing differences in these subtypes: luminal A patients “tend to have a good prognosis with lower recurrence rates” and treatment “is mainly based on hormonal therapy” (citing Kennecke et al, 2010), whereas luminal B1 “tend to have a higher recurrence rate and lower survival rates after relapse” (citing Ellis et al, 2008) and “poorer outcomes with hormone therapy, yet respond better to chemotherapy” (citing Ozlem et al, 2014). The specification describes that the claimed invention “is based on the surprising discovery that markers in Table 1 are upregulated in tissue samples of patients with luminal A (LA)-like breast cancer and downregulated in tissue samples of patients with luminal B1 (LB1)-like breast cancer, whereas markers in Table 2 are upregulated in in tissue samples of patients with LB1-like breast cancer and downregulated in tissue samples of patients with LA-like breast cancer” (¶ 9).
The scope of the claims is broad with respect to the markers to be used to distinguish ER-positive breast cancer between the LA and LB1 subtypes. The claims are genus claims because they are directed to detecting the expression levels of one or more biomarkers selected from the group listed in Tables 1 and 2. While the claims recite “detecting a level of a breast cancer marker”, they further indicate that “the breast cancer marker is one or more markers selected from Tables 1 and 2”; this aligns with the definition of “marker” in the specification at ¶ 138 as encompassing a panel of markers. Tables 1 and 2 together list 90 genes, 78 of which are stated to be upregulated in the LA-like subtype (Table 1), and 12 of which are stated to be upregulated in the LB-1 like subtype (Table 2). Thus, the claims broadly encompass determining the molecular subtype of LA-like or LB1-like based on measuring, in a sample from a patient, the expression level of any one single protein selected from the group of 90, or measuring any combination of the 90, including any 2 or more, up to all 90 together.
The claims are also broad with respect to the type of biological sample taken from the subject for diagnosis. While dependent claim 3 expressly recites that the sample is breast tissue (which encompasses healthy or tumorous tissue), breast tumor tissue, circulating tumor cells, disseminated tumor cells in bone marrow or exosomes, or breast ductal fluid exudents, the broadest claims encompass use of any type of sample, such as blood.
In support of the claimed invention, the specification provides a working example at pages 137-142, which include Tables 1-2 listing the 90 proteins described above. These are taught to be 78 proteins “up-regulated in LA-enriched (LA-like) breast cancer” and 12 proteins “up-regulated in LB-1 enriched (LB1-like) breast cancer”, which were identified as the “90 significant proteins” by “univariate analysis” of 674 differentially-expressed proteins.
While these proteomics results are worthy of further study, such results alone are not sufficient for the skilled artisan to practice the claimed method for differential diagnosis of LA versus LB1 subtypes of breast cancer. The relevant art prior to the claimed priority date of the instant application (4/6/21) does not appreciate that the identification of a differentially expressed biomarker in a proteomics study is sufficient for the skilled artisan (e.g. doctor) to use measurement of such to make a differential diagnosis as to the molecular subtype of breast cancer. Sallam et al (2015. Disease Markers, Volume 2015; pages 1-12), in a review titled “Proteomics in Cancer Biomarkers Discovery: Challenges and Applications”, teaches that the prior art appreciates multi-step strategies for “developing tumor biomarkers”, such as “the biomarker discovery, the development of an assay system, the performance of preliminary analysis for the biomarker’s clinical potential, the standardization and assessment of the biomarker’s measuring assay, and finally the validation of that assay for clinical use” (page 3). Thus, the prior art appreciated that identification of the differential expression of a biomarker in a proteomics study is only the beginning of a process that may or may not lead to a clinically valid biomarker. Sallam further teaches that, “High-throughput hypothesis-generating methods have revealed hundreds to thousands of cancer associated proteins (CAPs). This implies that hundreds to thousands of potential protein biomarkers have been suggested in the literature and are awaiting proper validation. It is only after validating these molecules that they can be considered for application in diverse clinical setting such as diagnosis, prognosis, disease staging, and patients’ categorization. This is a critical aspect in translational cancer research” (page 5). Thus, Sallam demonstrates the complexity appreciated in the prior art with respect to predicting whether one or more differentially expressed biomarkers is actually a valid diagnostic for differential diagnosis in cancer.
The post-filing date art of Bradley (“Translating Proteomics Research to Clinical Diagnosis”, Feb 2026, 10 pages as printed; available at https://www.technologynetworks.com/proteomics/articles/translating-proteomics-research-to-clinical-diagnostics-410071; pages 1-10 as printed) teaches that “[t]he translation from an analytically valid test to a clinically valid diagnostic is often where many candidate biomarkers fail” (page 5), and that:
“Clinical validation requires the deployment of the assay across large, independent, and well-characterized patient cohorts. These studies must be powered statistically to establish critical diagnostic metrics, including clinical sensitivity, clinical specificity, positive predictive value (PPV), and negative predictive value (NPV). Furthermore, understanding the inherent biological variability of the human proteome is paramount. Clinical laboratories must establish robust reference intervals (normal ranges) and precise clinical decision thresholds (cut-offs) that account for variables such as age, biological sex, comorbidities, and circadian rhythms. For multiplexed proteomic diagnostics, where algorithms combine multiple protein concentrations into a single risk score, the mathematical models themselves must be strictly locked and prospectively validated to prevent data overfitting” (page 6)
Thus, the post-filing date art also appreciates the unpredictability and large quantity of experimentation required to translate a candidate biomarker (e.g., a differentially expressed protein) into a validated biomarker suitable for use in clinical diagnosis. The instant specification, while containing a working example demonstrating differential expression of 90 proteins, does not provide any examples of translating one or more of these biomarkers into a biomarker that is clinically validated for differential diagnosis of luminal A and B1 subtypes of ER-positive breast cancer. While enablement does not necessarily require a working example, "[l]ack of a working example, however, is a factor to be considered, especially in a case involving an unpredictable and undeveloped art", per MPEP 2164.02. Thus, in order to practice the claimed method, the skilled artisan would first need to engage in experimentation to determine whether each individual biomarker, and each separate combination of biomarkers, of the 90 listed in Tables 1 and 2 can be used in such a manner clinically. Such experimentation, even to validate the use of a single biomarker or a single set of biomarkers for clinical diagnosis, would be undue in view of the amount of effort and time required. The outcome of such a study would generally be the focus of an entire publication in the relevant literature.
The scope of the biological sample encompassed by the claims adds further unpredictability as to whether the claimed method is fully enabled. As described above, the claims encompass a full range of biological samples, including blood samples, but even the limited working example is limited to measurements made with breast cancer tissue samples. There is no guidance provided by the specification as to whether the proteins of Table 1 and 2 are expressed in the same fashion in other tissues, e.g., blood, of breast cancer patients such that measuring the proteins in such samples can be used to distinguish luminal A and B1 subtypes.
In summary, due to the large quantity of experimentation necessary to determine whether measuring the expression levels in a biological sample of a subject of one or more (in any possible combination) of the 90 proteins listed in Table 1 and 2 can be used to differentially diagnose the luminal A and B1 molecular subtypes of ER-positive breast cancer, the limited guidance and working examples provided by the specification in comparison with the teachings of the prior art with regard to clinical validation of biomarkers to be used in breast cancer diagnosis, the complex nature of the invention, the state of the prior art which establishes unpredictability, and the breadth of the claims with respect to the number of markers, undue experimentation would be required of the skilled artisan to use the invention as claimed.
Conclusion
No claims are allowable.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to ZACHARY C HOWARD whose telephone number is (571)272-2877. The examiner can normally be reached on Monday to Friday from 9 AM to 5 PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Vanessa Ford, can be reached at telephone number (571) 272-0857. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of an application may be obtained from Patent Center. Status information for published applications may be obtained from Patent Center. Status information for unpublished applications is available through Patent Center to authorized users only. Should you have questions about access to the USPTO patent electronic filing system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).
Examiner interviews are available via a variety of formats. See MPEP § 713.01. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) Form at https://www.uspto.gov/InterviewPractice.
/ZACHARY C HOWARD/Primary Examiner, Art Unit 1674